Pfizer Inc. (PFE)
Pfizer: Growing Beyond Covid
Pfizer continues to transition to a strong future with reduced Covid drug sales. The biopharma has a strong lineup of new drugs whether via FDA approval or acquisition. The stock has a large dividend yield of 5.9%.
Pfizer data points to strong efficacy, particularly most at-risk groups
Pfizer Inc (NYSE:PFE, ETR:PFE) looks set to open higher Monday after it revealed that its late-stage trial for a Respiratory Syncytial Virus (RSV) vaccine showed strong neutralizing responses after a single dose in adults. The Phase 3 study tested Abrysvo against a placebo in people with immunocompromising conditions at risk for severe RSV-related lower respiratory tract disease.
Pfizer reports positive results in trial of vaccine for immunocompromised adults at risk of severe RSV-related illness
Pfizer Inc. PFE, -0.73% said Monday a substudy of a Phase 3 trial of a treatment for immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus-associated lower respiratory track disease achieved positive safety and immunogenicity results. The trial is evaluating two doses of the drug company's Abrysvo vaccine in treatment adults at increased risk of developing RSV-LTRD, Pfizer said in a statement.
Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised immune system.
Is Pfizer Stock a Buy Now After Earnings?
Pfizer posted positive growth during the second quarter, a heartening sign for shareholders. Strong demand for several products beyond its COVID-19 portfolio supports a positive outlook.
Forget Tech! 3 Value Stocks That Could Win Big From Rate Cuts.
Investors usually rush into tech stocks when rate cuts loom on the horizon, as they do now. Federal Reserve Chair Jerome Powell just said that those cuts could come in September.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
3 Cheap Stocks to Buy in August for Under $50
Finding the right stocks for investment can be a tricky game. While there are thousands of stocks to choose from, only a few can pass the test of time.
Pfizer: Tracking Well Above The Industry
Despite Wall Street's continued conservatism regarding its business prospects, Pfizer beat analysts' expectations for the second quarter of 2024. In addition to the raised full-year 2024 guidance, the company's remaining share repurchase authorization is $3.3 billion. Pfizer's oncology franchise sales reached $3.96 billion in the second quarter of 2024, up 25.6% year-on-year.
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Monday, BioNTech SE BNTX reported deeper losses in the second quarter of 2024, with an EPS loss of $(3.62) or (3.36) euros, missing the consensus of (1.89) euros and higher than (79) cents in the second quarter of 2023.
Is This Decision by Pfizer Bad News for Eli Lilly?
Eli Lilly is a giant in the world of weight loss drugs, generating billions of dollars in revenue. Rival big pharma player Pfizer aims to get in on this major market.
Can Pfizer (PFE) Run Higher on Rising Earnings Estimates?
Pfizer (PFE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
